Pharmaceutical, Medical
Cyrano Therapeutics
When Cyrano Therapeutics came to us, they had a science-backed product and a clinically urgent mission: help people regain their sense of smell and taste after chronic loss. What they didn’t have was a story anyone, let alone investors, would stop and read.
$1M
Valuation Before Sulfur
12.8M+
Valuation After Sulfur
WORK
Strategy, Technical Narrative Reframing, Investor Pitch Consulting, Regulatory Disclosures, Market Translation
INDUSTRY
Health Care, Medical, Medical Device, Therapeutics
TALENT
Scientists + Our Team
REGULATORY
SEC Capital Raise, Reg. D, Marketing, Pharma Therapeutic, and FTC.
CHALLENGE
This was a great company, awesome product, and a good mission. However, it’s complex to understand, navigate, and entice people to listen, let alone invest.
The initial opening pitch line:
“Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.”
Technically accurate, but also a total snooze.
SOLUTION
We asked a different question:
“What if you couldn’t smell or taste anymore?”
This was the theme: digest the complex technical and medical information and synthesize it to be appealing enough for investors to open and also attribute credibility to the science. In other words, not too technical but also not marketing jargon.
RESULTS
From a soft-spoken science pitch to a human-first story that landed. Hard. They didn’t just get meetings—they got backing. Cyrano’s valuation jumped from $1M to $12.8M, with investors seeing what we helped them see: a therapeutic with massive potential and a team worth betting on.
We rebuilt the pitch strategy from the inside out—rethinking narrative, positioning, and technical data inclusion.
We rewrote the pitch to lead with human emotion, not technical jargon—because investors back people, not molecules. Working closely with the executive team, we shaped a story that honored medical claims, SEC fundraising disclosures, and FTC advertising rules, while translating complex science into clear, compelling value—in under two minutes*.
*The typical amount of time a VC spends reviewing your pitch deck.
+12M
Capital Raised after Sulfur’s repositioning
2
Additional rounds of funding raised
-28
Page Reduction in Investment Deck
+82%
Open Rate of Cold Pitch Emails/Clicks
Change It Up.
Get Real Results.